The update is based on data from the FLEX study in patients with HR-positive, HER2-negative early-stage breast cancer.

CAR031's global reach," including in China, as a potential treatment for liver and other solid tumors, AbelZeta CEO Tony Liu said.

The firm filed data from the Phase III VIKTORIA-1 trial, which evaluated gedatolisib with fulvestrant with or without a CDK4/6 inhibitor.

The companies struck the deal as Atsena prepares to initiate enrollment of a pivotal cohort of its lead program in XLRS.

The company is restarting its solid tumor program with the Phase I trial after the company paused it to focus on blood cancer.

The firm reported positive results this week from a biomarker analysis in a Phase IIb trial of OST-HER2, which it will submit to regulators.

The announcement comes on the heels of promising preliminary Phase II data, in which OCU410 reduced lesion growth in patients' eyes.

After JP Morgan, the company is focusing on getting ready to submit a biologics license application to the FDA for miv-cel in ...

The company has started enrolling patients into a run-in period for the Phase III study, and plans to begin dosing later this ...

The grant will support a Phase I study of an anti-CD64 CAR T-cell therapy in patients with acute myeloid leukemia.